Concepedia

Author

Douglas E. Dylla

AbbVie (United States)ORCID

Also Known As

D. Dylla, D.E. Dylla, Doug E Dylla, Douglas Dylla, Douglas E Dylla, Douglas E. Dylla

30

Publications

439

Citations

12

H-Index

10

Concepts

All Affiliations

AbbVie (United States)University of IowaInsermClinical Research InstituteImperial College Healthcare NHS Trust
DE

About

Douglas E. Dylla is an author at AbbVie (United States) specializing in pathogenesis, viral pathogenesis, and virology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

149

2

Immunology

2

2

149

3

Allergy

1

1

31

4

Biomolecular Engineering

1

1

118

5

Cell Biology

1

1

118

Douglas E. Dylla

×

11

Publications

344

Citations

11

H-Index

YearCitations

Lentivirus Vectors Pseudotyped with Filoviral Envelope Glycoproteins Transduce Airway Epithelia from the Apical Surface Independently of Folate Receptor Alpha

Patrick L. Sinn, Melissa A. Hickey, Patrick D. Staber,

Journal of Virology

2003

118

Lentiviral Vector Gene Transfer to Porcine Airways

Patrick L. Sinn, Ashley L. Cooney, Mayumi Oakland,

Molecular Therapy — Nucleic Acids

2012

47

Basolateral Entry and Release of New and Old World Arenaviruses from Human Airway Epithelia

Douglas E. Dylla, Daniel E. Michele, Kevin P. Campbell,

Journal of Virology

2008

31

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Eli Zuckerman, Julio Gutiérrez, Douglas E. Dylla,

Clinical Gastroenterology and Hepatology

2020

27

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

Edward Gane, Victor de Lédinghen, Douglas E. Dylla,

Journal of Viral Hepatitis

2021

26

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

Steven L. Flamm, Jens Kort, Steven E. Marx,

Advances in Therapy

2020

25

Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism

Douglas E. Dylla, Litao Xie, Daniel E. Michele,

Genetic Vaccines and Therapy

2011

19

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Xavier Forns, Jordan J. Feld, Douglas E. Dylla,

Advances in Therapy

2021

13

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

Philippe J. Zamor, Ashley Brown, Douglas E. Dylla,

The American Journal of Gastroenterology

2021

13

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations

Dwaipayan Mukherjee, Michelle A. Collins, Douglas E. Dylla,

Infectious Diseases and Therapy

2023

13

Page 1